York and Belfast, UK (August 19th, 2021) – Aptamer Group, the developer of custom affinity ligands to enable the life science …
Type and hit ENTER
David Ribeiro
As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce two new appointments within …
June 21, 2021
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it has entered into an exclusive licensing agreement with …
June 7, 2021
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of Geneva and the University Hospital of Geneva, today …
February 21, 2021
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that …
December 14, 2020
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact Innovate UK grant as …
December 10, 2020
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as a Gold Level Innovator …
December 2, 2020
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that …
November 19, 2020
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces a significant …
October 16, 2020
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of …
August 3, 2020
Posted by David Ribeiro
Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® technology. The company is …
July 27, 2020
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it will be conducting a collaborative 12-month project with the Northern Ireland …
July 9, 2020
Posted by David Ribeiro
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, has formed a new partnership with Ulster University, the largest university in Northern Ireland. The …
June 29, 2020
Posted by David Ribeiro
ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company in the newly created …
June 23, 2020
Posted by David Ribeiro
ProAxsis is delighted to have been shortlisted for a Business Eye First Trust Award for the second year running. Having been …
November 18, 2019
Posted by David Ribeiro
ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s University, Belfast. For the second year running, the …
October 25, 2019
Posted by David Ribeiro
ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate …
October 25, 2019
Posted by David Ribeiro
The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic …
November 26, 2018
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
September 20, 2018
Posted by David Ribeiro
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European …
September 18, 2018
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
August 2, 2018
Posted by David Ribeiro
ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK. …
June 18, 2018
Posted by David Ribeiro
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for …
June 4, 2018
Posted by David Ribeiro
ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative …
June 1, 2018
Posted by David Ribeiro
ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place …
May 2, 2018
Posted by David Ribeiro
ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School of Medicine, Dentistry and …
March 6, 2018
Posted by David Ribeiro
Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel …
February 15, 2018
Posted by David Ribeiro
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
RECENT NEWS
-
January 7, 2022
ProAxsis Ltd CEO Update Report – End Q4 2021
-
January 6, 2022
ProAxsis establishes new internal Finance team
-
November 15, 2021
ProAxsis releases new NEATstik® data at the Irish Thoracic Society Conference 2021
Copyright © 2016-2021 - ProAxsis - All rights reserved.
David Ribeiro, Author at ProAxsis